Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This study was performed to evaluate the safety, tolerability, activity, pharmacokinetics
(PK), and daily dose regimen of KD025 administered orally (PO) for 12 weeks to subjects with
psoriasis vulgaris who failed at least one line of systemic therapy.